Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Lizard King's Trading Swamp -- Ignore unavailable to you. Want to Upgrade?

To: LzzrdKing who wrote (7082)	8/7/1999 9:53:00 PM
From: LzzrdKing	Respond to of 7396

Another I like is UTHR. Great chart here is some first call from alex brown HIGHLIGHTS: -- We are initiating research coverage of United Therapeutics with a STRONG BUY investment rating on the shares and a 12-month price target of $33. With two potential breakthrough products rapidly advancing through Phase III trials, United Therapeutics is poised to become a highly profitable pharmaceutical company with exceptional earnings growth prospects within two years, in our view. -- The Company's two lead products, UT-15 and beraprost, could generate combined annual sales of $500+ million, we estimate. UT-15 is poised to become the first safe, effective and minimally invasive treatment for advanced pulmonary hypertension, while beraprost represents a major advance in the treatment of peripheral vascular disease. -- Development and commercial risk associated with both products appears low, in our opinion. Both UT-15 and beraprost are supported by strong clinical data. Our confidence in UT-15's prospects is further bolstered by the extremely high level of enthusiasm voiced by approximately one dozen clinical experts with whom we have consulted. With respect to beraprost, this product already has achieved annual sales in excess of $200 million in Japan and is likely to soon be approved in Europe based on an already completed Phase III trial. -- Importantly, United Therapeutics has retained the lion's share of commercial rights to both of its lead products. Hence, we believe that the Company's earnings leverage could be very substantial. We are projecting fully taxed EPS of $0.43 in 2001, $1.71 in 2002, and $3.53 in 2003.